MARKET

LPCN

LPCN

Lipocine Inc
NASDAQ
0.4567
-0.0199
-4.18%
Pre Market: 0.4700 +0.0133 +2.91% 08:00 11/29 EST
OPEN
0.4800
PREV CLOSE
0.4766
HIGH
0.4930
LOW
0.4460
VOLUME
20
TURNOVER
--
52 WEEK HIGH
1.890
52 WEEK LOW
0.3600
MARKET CAP
40.42M
P/E (TTM)
9.82
1D
5D
1M
3M
1Y
5Y
BRIEF-Lipocine Announces Financial Results For The Third Quarter
Reuters · 11/09 14:23
Lipocine GAAP EPS of -$0.03 in-line
Seekingalpha · 11/09 13:30
Lipocine Q3 EPS $(0.03) Up From $(0.04) YoY
Benzinga · 11/09 13:13
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the third quarter and ni...
PR Newswire · 11/09 13:00
BRIEF-Lipocine Appoints Spyros Papapetropoulos As Lead Director And Chairman Of Board
Reuters · 11/03 12:49
Lipocine Named Spyros Papapetropoulos, M.D. Ph.D., Chairman of the Board.
Benzinga · 11/03 10:13
Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products through the oral delivery of previously difficult to deliver molecules focused on treating CNS disorders, an...
PR Newswire · 10/11 12:00
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Reshape Lifesciences (NASDAQ:RSLS) shares increased by 12.7% to $0.34 during Monday's after-market session. The market value of their outstanding shares is at $1.2 million.
Benzinga · 10/10 21:51
More
About LPCN
Lipocine Inc. is a clinical-stage biopharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on neuroendocrine and metabolic disorders. It has a portfolio of product candidates that target unmet needs for neurological and psychiatric central nervous system (CNS) disorders, liver diseases, and hormone supplementation for men and women. The Company's product candidate, TLANDO, is an oral testosterone replacement therapy (TRT) comprised of testosterone undecanoate (TU). Its additional pipeline candidates include LPCN 1148, LPCN 1144, LPCN 1111 (TLANDO XR), LPCN 1107, LPCN 1154 and LPCN 2101. Its LPCN 1144 is an oral prodrug of bioidentical testosterone comprised of TU for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) which has completed Phase II testing. Its TLANDO XR is an oral TRT product comprised of testosterone tridecanoate (TT), which has completed Phase II trials.

Webull offers kinds of Lipocine Inc stock information, including NASDAQ:LPCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPCN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LPCN stock methods without spending real money on the virtual paper trading platform.